Your session is about to expire
← Back to Search
Study Summary
This trial is testing whether a lower dose of the steroid dexamethasone given during surgery can reduce postoperative pain and the need for opioids without increasing other complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I need to have hardware removed from my knee replacement.I have a fungal infection in my body.I am older than 18 years.I stayed in the hospital overnight after my surgery.I am under 18 years old.I will be discharged from the hospital on the same day of my procedure.I have not taken corticosteroids in the 3 months before surgery.I have inflammatory arthritis.I have kidney or liver failure.I am having or have had a partial or complete knee replacement surgery.I am having or have had a total knee replacement.
- Group 1: Group 1
- Group 2: Group 2
- Group 3: Group 3
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any related experiments that have been conducted within Group 1?
"The Manitoba Blood & Marrow Transplant Program CancerCare Manitoba conducted the first Group 1 research in 2002. Since then, 1098 trials have concluded and 553 are still running actively - notably many of them hosted at Rochester, Minnesota."
How many individuals are participating in this exploration?
"For this medical investigation to be successful, 429 individuals who meet the established criteria must take part. Among other places, Mayo Clinic Institutional Review in Rochester, Minnesota and Columbia University Irving Medical Center in New york will act as sites for enrolment."
In what scenarios is Group 1 typically administered?
"Group 1 is recommended for the treatment of ophthalmia, sympathetic eye disorder, and branch retinal vein occlusion."
Has Group 1 acquired the necessary authorization from the FDA?
"In our assessment, Group 1 earned a 3 for safety due to the successful completion of Phase 4 trials and ultimate approval by regulatory bodies."
Are there any vacancies to join this investigation?
"Yes, the records available on clinicaltrials.gov affirm that this trial is currently recruiting individuals to participate. Initially posted on October 28th 2021 and most recently updated just a few weeks ago, 429 patients are needed from 8 different sites."
Are there extensive sites in North America that are carrying out this research?
"The Mayo Clinic Institutional Review Board in Rochester, Minnesota, the Columbia University Irving Medical Center of New york City and Shiley Center for Orthopaedic Research and Education at Scripps Clinic in La Jolla, California are a few of the sites recruiting participants. Additionally, there is another 8 trial locations."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger